Cold-Stored Platelets: A Safer, Faster Option for Managing Active Bleeding and Trauma
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, posted on LinkedIn:
”Cold-Stored Platelets (CSPs): A Practical Tool for Treating Active Bleeding
Cold-stored platelets (CSPs) are platelets stored at 1-6°C instead of the conventional room temperature (20-24°C). Growing evidence shows that CSPs better preserve immediate hemostatic function, reduce bacterial contamination risk, and offer practical advantages in hemorrhage and trauma settings when standard platelets are limited or unavailable.
Why Transfusion Services Should Pay Attention
Improved Early Hemostatic Effect
- CSPs demonstrate enhanced clot formation and stronger platelet function in vitro.
- Clinical data suggest benefit in active bleeding, especially in trauma and surgical patients.
Lower Bacterial Risk and Extended Usable Life
- Cold storage significantly limits bacterial proliferation compared to room-temperature platelets.
- Under validated protocols, CSPs may be stored for up to 14 days for specific therapeutic indications.
Targeted Clinical Use
Current evidence and guidance support CSPs mainly for treatment of active bleeding,
not for routine prophylactic platelet transfusion.
Use should align with regulatory approval, institutional policy, and transfusion-committee guidance.
Operational Notes for Blood Banks and Transfusion Laboratories
Validated SOPs Are Essential
CSPs must be stored strictly at 1-6°C.
Visual inspection for platelet aggregates or clumping is required before issue.
Dual Inventory Strategy
- Maintain both cold-stored and room-temperature platelets.
- Clearly define clinical indications for each product type.
Ongoing Monitoring and Quality Review
- Track clinical outcomes, utilization patterns, and adverse events.
- Stay updated with ongoing clinical trials and evolving regulatory recommendations.
Bottom Line
Cold-stored platelets are an evidence-based, complementary option for managing active bleeding, offering:
- Faster hemostatic response
- Reduced bacterial risk
- Operational advantages in emergency settings
However, successful use depends on careful implementation, validated procedures, and clearly defined clinical indications.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch